Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12576231rdf:typepubmed:Citationlld:pubmed
pubmed-article:12576231lifeskim:mentionsumls-concept:C0026769lld:lifeskim
pubmed-article:12576231lifeskim:mentionsumls-concept:C0028944lld:lifeskim
pubmed-article:12576231lifeskim:mentionsumls-concept:C0017968lld:lifeskim
pubmed-article:12576231lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:12576231lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:12576231lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:12576231lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:12576231pubmed:issue1-2lld:pubmed
pubmed-article:12576231pubmed:dateCreated2003-2-10lld:pubmed
pubmed-article:12576231pubmed:abstractTextHumoral auto-immunity to the myelin oligodendrocyte glycoprotein (MOG) is likely involved in the pathogenesis of multiple sclerosis (MS). In 44 MS patients and 30 controls, Ig-producing B cells were identified by their isotype and as MOG-specific spot-forming cells (SFC). Peripheral anti-MOG antibodies were assayed in ELISA as well as anti-butyrophilin antibodies to investigate for molecular mimicry. MS patients had significantly higher levels of IgA- and MOG-SFC than controls, as well as significantly higher antibody responses to MOG and butyrophilin. These data provide added support for the implication of anti-MOG humoral immunity in the pathophysiology of MS, and suggest a balance of systemic (anti-self) and mucosal (environment-modulated) immune reactions in an attempt at regulating the pathogenic specific immune response.lld:pubmed
pubmed-article:12576231pubmed:languageenglld:pubmed
pubmed-article:12576231pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12576231pubmed:citationSubsetIMlld:pubmed
pubmed-article:12576231pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12576231pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12576231pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12576231pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12576231pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12576231pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12576231pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12576231pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12576231pubmed:statusMEDLINElld:pubmed
pubmed-article:12576231pubmed:monthFeblld:pubmed
pubmed-article:12576231pubmed:issn0165-5728lld:pubmed
pubmed-article:12576231pubmed:authorpubmed-author:BénéM CMClld:pubmed
pubmed-article:12576231pubmed:authorpubmed-author:FaureG CGClld:pubmed
pubmed-article:12576231pubmed:authorpubmed-author:Kolopp-SardaM...lld:pubmed
pubmed-article:12576231pubmed:authorpubmed-author:Kennel De...lld:pubmed
pubmed-article:12576231pubmed:authorpubmed-author:De BouwerieMMlld:pubmed
pubmed-article:12576231pubmed:authorpubmed-author:BernardC C...lld:pubmed
pubmed-article:12576231pubmed:issnTypePrintlld:pubmed
pubmed-article:12576231pubmed:volume135lld:pubmed
pubmed-article:12576231pubmed:ownerNLMlld:pubmed
pubmed-article:12576231pubmed:authorsCompleteYlld:pubmed
pubmed-article:12576231pubmed:pagination117-25lld:pubmed
pubmed-article:12576231pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:12576231pubmed:meshHeadingpubmed-meshheading:12576231...lld:pubmed
pubmed-article:12576231pubmed:meshHeadingpubmed-meshheading:12576231...lld:pubmed
pubmed-article:12576231pubmed:meshHeadingpubmed-meshheading:12576231...lld:pubmed
pubmed-article:12576231pubmed:meshHeadingpubmed-meshheading:12576231...lld:pubmed
pubmed-article:12576231pubmed:meshHeadingpubmed-meshheading:12576231...lld:pubmed
pubmed-article:12576231pubmed:meshHeadingpubmed-meshheading:12576231...lld:pubmed
pubmed-article:12576231pubmed:meshHeadingpubmed-meshheading:12576231...lld:pubmed
pubmed-article:12576231pubmed:meshHeadingpubmed-meshheading:12576231...lld:pubmed
pubmed-article:12576231pubmed:meshHeadingpubmed-meshheading:12576231...lld:pubmed
pubmed-article:12576231pubmed:meshHeadingpubmed-meshheading:12576231...lld:pubmed
pubmed-article:12576231pubmed:meshHeadingpubmed-meshheading:12576231...lld:pubmed
pubmed-article:12576231pubmed:meshHeadingpubmed-meshheading:12576231...lld:pubmed
pubmed-article:12576231pubmed:meshHeadingpubmed-meshheading:12576231...lld:pubmed
pubmed-article:12576231pubmed:meshHeadingpubmed-meshheading:12576231...lld:pubmed
pubmed-article:12576231pubmed:meshHeadingpubmed-meshheading:12576231...lld:pubmed
pubmed-article:12576231pubmed:meshHeadingpubmed-meshheading:12576231...lld:pubmed
pubmed-article:12576231pubmed:meshHeadingpubmed-meshheading:12576231...lld:pubmed
pubmed-article:12576231pubmed:meshHeadingpubmed-meshheading:12576231...lld:pubmed
pubmed-article:12576231pubmed:year2003lld:pubmed
pubmed-article:12576231pubmed:articleTitleAnti-myelin oligodendrocyte glycoprotein B-cell responses in multiple sclerosis.lld:pubmed
pubmed-article:12576231pubmed:affiliationLaboratoire d'Immunologie du CHU, Faculté de Médecine, BP 184, 54500 Vandoeuvre les, 54000, Nancy, France.lld:pubmed
pubmed-article:12576231pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12576231pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12576231lld:pubmed